biostudies-literatureUnknown55Paccoud O<h4>Background</h4>Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France.<h4>Methods</h4>We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables.<h4>Findings</h4>We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, inThe Lancet regional health. Europe101365https://www.ebi.ac.uk/biostudies/studies/S-EPMC12426822biostudies-literatureYeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.PMC12426822Imbert SFavennec LPihet MChesnay ABonhomme JGangneux JPCassaing SBoukris-Sitbon KPoirier PDesbois-Nogard NChouaki THuguenin ALortholary OBougnoux MEPaccoud ODalle FMorio FFrench Mycoses Study GroupNicolas MDemar MMariani PDurieux MFMahinc CLanternier FPaugam ABellanger APChachaty EAlanio ALetscher-Bru VPerraud-Cateau EObadia TDesnos-Ollivier MDesoubeaux GMicaelo MSasso MMerabet LHasseine LfalseYeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.<h4>Background</h4>Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France.<h4>Methods</h4>We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables.<h4>Findings</h4>We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, in2025-01-01T00:00:00Z2025 Aug2026-06-01T15:56:55.279Z2026-04-08T13:55:53.153ZS-EPMC124268224095095010.1016/j.lanepe.2025.101365